Search Results for: Years

Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial.

Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial.

Coronavirus Literature
Publication date: Jun 04, 2026 This trial evaluated co-administration of the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) and an Omicron XBB. 1.5-based COVID-19 mRNA vaccine ... Read more